

2nd Long-acting Treatment and Prevention Conference

Future of antiretrovirals in Africa: Long-acting agents and beyond

29 October 2024 | Johannesburg

PROVISIONAL PROGRAMME

Start time	Topic	Proposed speaker
07:30	Arrival, registration and refreshments	
08:30	Welcome and introduction by the Chairs	Catherine Orrell and Nosisa Sipambo
08:35	Opening plenary talk: Long-acting agents - where do these products fit in the African context?	Catherine Orrell
New kids on the block: Industry Update		
08:55	Long-acting injectable cabotegravir	
09:10	MK-8527 (and ISL) trials	
09:25	GS-6207: long acting HIV capsid inhibitor	
09:40	Q & A	All
The Future of Long acting ARVs (Treatment)		
09:50	Is injectable treatment as effective in maintaining viral suppression as standard oral antiretroviral treatment – evidence from the CARES trial	Simiso Sokhela
10:10	Improved access: Effectiveness, and cost-effectiveness, of 2-monthly injectable long-acting antiretroviral therapy	Nigel Garrett
10:30	Tea break	
The Future of Long acting ARVs (Treatment)		
11:00	Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection: Efficacy and safety results of the CAPELLA study	
11:20	What is the role of lenacapavir in future first-line HIV treatment?	Francois Venter
11:40	How long-acting injectable ART could help Adolescent and Young Adults	Lauren Jennings
12:00	Q & A	All
The Future of Long acting ARVs (Prevention)		
12:10	Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection (PURPOSE 1)	
12:30	Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa (AXIS)	
12:50	Uptake and retention of adolescents and young adults in differentiated HIV prevention	
13:10	Q & A	All
13:20	Lunch break	
Special populations:		
14:15	Plenary talk: LA medications: Where do they fit in for niche populations in an African context?	Lee Fairlie
14:45	Pregnancy studies - prevention	
15:00	Pregnancy studies - treatment	
15:15	Advancements in Neonatal HIV Therapy	Adrie Bekker
15:30	Progress towards bringing Long-acting ART to children and adolescents	Mo Archary
15:50	Q & A	All
16:00	Tea break	
Implementation: TIME FOR ACTION		
16:25	FASTPrEP study (sub study - Prepare to Choose) - implementation	
16:45	PrEP LA implementation in Botswana	
17:05	LA implementation in Zambia	
17:25	South African perspective - where are with implementation, and what is the plan?	
17:45	Discussion & Closing	Catherine Orrell and Nosisa Sipambo